Insider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Purchases $16,301.63 in Stock

Key Points

• Director Ramiro Guerrero bought 11,899 MAIA shares at an average price of $1.37, investing $16,301.63 and increasing his position by 2.02% to 600,117 shares.
• MAIA shares fell 2.9% to $1.35, while the company reported a quarterly loss of $0.13 per share, missing analyst expectations by $0.02.
• Several hedge funds established new positions in MAIA, including Solas Capital Management’s approximately $4.36 million stake; institutional investors collectively own 5.65% of the company.

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Ramiro Guerrero acquired 11,899 shares of MAIA Biotechnology stock in a transaction that occurred on Thursday, August 20th. The shares were purchased at an average price of $1.37 per share, with a total value of $16,301.63. Following the transaction, the director owned 600,117 shares of the company's stock, valued at $822,160.29. The trade was a 2.02% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

MAIA Biotechnology Stock Down 2.9%

Shares of MAIA Biotechnology stock traded down $0.04 during trading hours on Monday, reaching $1.35. 227,366 shares of the stock traded hands, compared to its average volume of 804,487. MAIA Biotechnology, Inc. has a one year low of $0.87 and a one year high of $3.19. The firm has a market capitalization of $82.12 million, a price-to-earnings ratio of -2.18 and a beta of 0.24. The company has a 50 day moving average price of $1.37 and a 200 day moving average price of $1.46.

MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Sell-side analysts anticipate that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current year.

Institutional Trading of MAIA Biotechnology

Hedge funds have recently bought and sold shares of the stock. Solas Capital Management LLC purchased a new stake in MAIA Biotechnology in the 2nd quarter worth approximately $4,364,000. Centric Wealth Management purchased a new stake in shares of MAIA Biotechnology in the second quarter worth $1,107,000. Cable Car Capital LP bought a new stake in shares of MAIA Biotechnology during the 2nd quarter valued at $741,000. BlackRock Inc. bought a new stake in shares of MAIA Biotechnology during the 2nd quarter valued at $580,000. Finally, Corsair Capital Management L.P. purchased a new position in shares of MAIA Biotechnology during the 1st quarter valued at $140,000. Institutional investors own 5.65% of the company's stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source